Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Digital Health Innovation

QUOTED. 27 April 2020. David Maman.

  • News

Executive Summary

Israel-based start-up Binah.ai is gearing up for a post-pandemic world where screening technologies will play an increasingly important role. See what David Maman, CEO of Binah.ai, said about it here.

“This is a key traumatic point in our history where telemedicine undoubtedly will suppress classical and traditional medical services within the next 18 to 24 months.” – David Maman, CEO, Binah.ai

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Digital Health Innovation
Latest Headlines

UK MHRA Updates Assistive Tech And Borderline Regulations

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

See All
UsernamePublicRestriction

Register

MT126643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By